Skip to main navigation Skip to search Skip to main content

A Phase III, randomized, multicenter, parallel-group, noninferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus longacting rilpivirine from current INI-NNRTI, or PI

University at Buffalo

Project: Research

Project Details

StatusFinished
Effective start/end date02/15/17 → 12/31/23

Funding

  • GlaxoSmithKline: $146,731.16